PL2531501T3 - Inhibitory kinazy 1 regulującej sygnał apoptotyczny - Google Patents

Inhibitory kinazy 1 regulującej sygnał apoptotyczny

Info

Publication number
PL2531501T3
PL2531501T3 PL11701347T PL11701347T PL2531501T3 PL 2531501 T3 PL2531501 T3 PL 2531501T3 PL 11701347 T PL11701347 T PL 11701347T PL 11701347 T PL11701347 T PL 11701347T PL 2531501 T3 PL2531501 T3 PL 2531501T3
Authority
PL
Poland
Prior art keywords
inhibitors
apoptosis signal
regulating kinase
kinase
regulating
Prior art date
Application number
PL11701347T
Other languages
English (en)
Inventor
Edcon Chang
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PL2531501T3 publication Critical patent/PL2531501T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
PL11701347T 2010-02-03 2011-01-21 Inhibitory kinazy 1 regulującej sygnał apoptotyczny PL2531501T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30086910P 2010-02-03 2010-02-03
PCT/US2011/022137 WO2011097079A1 (en) 2010-02-03 2011-01-21 Apoptosis signal-regulating kinase 1 inhibitors
EP11701347.4A EP2531501B1 (en) 2010-02-03 2011-01-21 Apoptosis signal-regulating kinase 1 inhibitors

Publications (1)

Publication Number Publication Date
PL2531501T3 true PL2531501T3 (pl) 2014-05-30

Family

ID=43645892

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11701347T PL2531501T3 (pl) 2010-02-03 2011-01-21 Inhibitory kinazy 1 regulującej sygnał apoptotyczny

Country Status (14)

Country Link
US (2) US8802695B2 (pl)
EP (1) EP2531501B1 (pl)
JP (1) JP5711270B2 (pl)
CN (1) CN102834393B (pl)
CA (1) CA2787360C (pl)
DK (1) DK2531501T3 (pl)
ES (1) ES2445917T3 (pl)
HR (1) HRP20140114T1 (pl)
PL (1) PL2531501T3 (pl)
PT (1) PT2531501E (pl)
RS (1) RS53176B (pl)
SI (1) SI2531501T1 (pl)
SM (1) SMT201400012B (pl)
WO (1) WO2011097079A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
MX2012015105A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Inhibidores de cinasa de regulacion mediante señal de apoptosis.
JP5927201B2 (ja) 2010-12-16 2016-06-01 カルチャン リミテッド Ａｓｋ１阻害ピロロピリミジン誘導体
AU2012301617A1 (en) 2011-09-02 2014-04-17 Salk Institute For Biological Studies CaMKII, IP3R, calcineurin, p38 and MK2/3 inhibitors to treat metabolic disturbances of obesity
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
RU2014149136A (ru) * 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
AU2014358668B2 (en) * 2013-12-04 2019-10-24 Galmed Research & Development Ltd. Aramchol salts
TW201618781A (zh) 2014-08-13 2016-06-01 吉李德科學股份有限公司 治療肺高血壓之方法
MX2017003933A (es) 2014-09-24 2017-06-30 Gilead Sciences Inc Metodos de tratamiento de la enfermedad hepatica.
EP4276095A3 (en) 2014-12-23 2024-01-17 Gilead Sciences, Inc. Processes for preparing ask1 inhibitors
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
US10849911B2 (en) 2015-06-10 2020-12-01 Galmed Research And Development Ltd. Low dose compositions of Aramachol salts
JPWO2017169503A1 (ja) * 2016-04-01 2019-02-14 国立大学法人千葉大学 含窒素芳香族アミドの製造方法、ピロール・イミダゾールポリアミドの製造方法、及び化合物
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
ES2938615T3 (es) 2016-08-15 2023-04-13 Bayer Cropscience Ag Derivados del heterociclo bicíclico condensado como agentes de control de plagas
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
JOP20190221A1 (ar) * 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
JP7377718B2 (ja) 2017-05-12 2023-11-10 エナンタ ファーマシューティカルズ インコーポレイテッド アポトーシスシグナル調節キナーゼ１阻害剤およびその使用方法
WO2018218044A2 (en) * 2017-05-25 2018-11-29 Enanta Pharmaceuticals Inc Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218042A1 (en) * 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10450301B2 (en) 2017-05-25 2019-10-22 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN110770233B (zh) * 2017-06-19 2022-07-26 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
US10597382B2 (en) 2017-08-28 2020-03-24 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11434249B1 (en) 2018-01-02 2022-09-06 Seal Rock Therapeutics, Inc. ASK1 inhibitor compounds and uses thereof
KR102798464B1 (ko) 2018-05-02 2025-04-21 이난타 파마슈티칼스, 인코포레이티드 아폽토시스 신호 조절 키나제 1 억제제를 포함하는 테트라졸 및 이의 사용 방법
WO2019213239A1 (en) 2018-05-02 2019-11-07 Enanta Pharmaceuticals Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US20210395241A1 (en) * 2018-07-03 2021-12-23 Novartis Ag Nlrp modulators
CN113227070A (zh) * 2018-08-14 2021-08-06 比奥根Ma公司 Ask1抑制剂
US10968199B2 (en) 2018-08-22 2021-04-06 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11345699B2 (en) 2018-11-19 2022-05-31 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020198214A1 (en) * 2019-03-25 2020-10-01 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CA3139809A1 (en) * 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Antibody drug conjugates
CN111808079A (zh) * 2020-08-05 2020-10-23 中国药科大学 吲哚类ask1小分子抑制剂及其制备方法和应用
KR20230127271A (ko) * 2020-12-28 2023-08-31 셀진 코포레이션 헤테로시클릭 화합물 및 기생충성 질환을 위한 그의용도
JP2025531844A (ja) * 2022-09-08 2025-09-25 ブリッジ メディシンズ Ｅｎｌ／ａｆ９ ｙｅａｔｓ及びｆｌｔ３の阻害剤
CN115368352B (zh) * 2022-10-25 2023-08-15 南京盛德瑞尔医药科技有限公司 一种葡萄糖激酶激动剂及其制备方法和应用
CN117122288B (zh) * 2023-09-08 2024-10-18 太原理工大学 基于锚定卷积网络的癫痫脑电信号预警方法及装置

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4062950A (en) 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
DE3347565A1 (de) 1983-12-30 1985-07-11 Thomae Gmbh Dr K Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPS6354321A (ja) 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
AU648523B2 (en) 1989-10-25 1994-04-28 Salk Institute For Biological Studies, The Receptor infection assay
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
JPH06503642A (ja) 1990-09-21 1994-04-21 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ プロトオンコタンパク質ｃ−ＪＵＮとホルモン受容体との間の機能的拮抗作用
DK0526171T3 (da) 1991-07-30 1997-08-25 Ajinomoto Kk Krystaller af N-(trans-4-isopropylcyclohexylcarbonyl)-Dphenylalanin og fremgangsmåder til fremstilling deraf
US5866563A (en) 1991-09-30 1999-02-02 The University Of British Columbia Vanadium compositions
EP0619842A1 (en) 1991-12-06 1994-10-19 The Salk Institute For Biological Studies Multimeric forms of members of the steroid/thyroid superfamily of receptors
ATE365209T1 (de) 1992-05-14 2007-07-15 Baylor College Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
CA2160135A1 (en) 1993-04-07 1994-10-13 Donald P. Mcdonnell Method for screening for receptor agonists
US6074861A (en) 1993-04-15 2000-06-13 National Jewish Center For Immunology And Respiratory Medicine MEKK proteins
US5981265A (en) 1993-04-15 1999-11-09 National Jewish Center For Immunology And Respiratory Medicine Methods for regulating MEKK protein activity
US5506102A (en) 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
EP0743520A3 (en) 1993-12-30 1999-11-10 The Salk Institute For Biological Studies Novel uses for GAL4-receptor constructs
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
DE4416433A1 (de) 1994-05-10 1995-11-16 Hoechst Ag Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten
US5488510A (en) 1994-07-26 1996-01-30 Lemay; Edward J. Enhanced depth perception viewing device for television
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
EP0832066B1 (en) 1995-06-06 2001-09-12 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
CA2342471C (en) 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
EP0859771A4 (en) 1995-10-31 2000-03-15 Merck & Co Inc SUBSTITUTED PYRIDYLPYRROLE, PREPARATIONS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE USE THEREOF
AU2090897A (en) 1996-02-29 1997-09-16 Mikael Bols Hydroxyhexahydropyridazines
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
JP3839103B2 (ja) 1996-04-19 2006-11-01 財団法人癌研究会 アポトーシス誘導タンパク質およびそれをコードする遺伝子
EP1019043A4 (en) 1996-05-07 2003-07-30 Univ Pennsylvania INHIBITORS OF GLYCOGEN SYNTHESIS KINASE 3 AND METHOD FOR THEIR IDENTIFICATION AND USE
WO1997046556A1 (en) 1996-06-07 1997-12-11 Merck & Co., Inc. OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
ATE215369T1 (de) 1996-09-05 2002-04-15 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische agonisten
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
FR2755439B1 (fr) 1996-11-05 1998-12-24 Virbac Sa Derives aryloxypropanolamines, leur procede de preparation et leurs applications
JP2001504490A (ja) 1996-11-20 2001-04-03 メルク エンド カンパニー インコーポレーテッド トリアリール置換イミダゾール、そのような化合物を含む組成物及び使用方法
EP0959885A4 (en) 1996-11-20 2002-07-17 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE
EP0959886A4 (en) 1996-11-20 2001-05-02 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS
US5880139A (en) 1996-11-20 1999-03-09 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
US5952322A (en) 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
EP0968209A1 (en) 1997-01-28 2000-01-05 Merck & Co., Inc. THIAZOLE BENZENESULFONAMIDES AS $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
AU6290998A (en) 1997-03-07 1998-09-29 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1017697A1 (en) 1997-09-23 2000-07-12 Novo Nordisk A/S MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
UA57811C2 (uk) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
JP2001525398A (ja) 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー 選択的β３アドレナリン作動性アゴニスト
AU2610299A (en) 1998-02-05 1999-08-23 Novo Nordisk A/S Hydrazone derivatives
US5998463A (en) 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP1062218A1 (en) 1998-03-12 2000-12-27 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
WO1999046244A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
WO1999046236A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
WO1999046237A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
WO1999046267A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
CA2289621A1 (en) 1998-03-16 1999-09-23 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (fbpase)
EP1073643B1 (en) 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
CA2330555A1 (en) 1998-05-12 1999-11-18 Jay Edward Wrobel Naphtho[2,3-b]heteroar-4-yl derivatives
US6057316A (en) 1998-05-12 2000-05-02 American Home Products Corporation 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes
ATE229015T1 (de) 1998-05-12 2002-12-15 Wyeth Corp Zur behandlung von insulin-resistenz und hyperglycemie geeignete biphenyl-oxo-essigsäuren
US6001867A (en) 1998-05-12 1999-12-14 American Home Products Corporation 1-aryl-dibenzothiophenes
EP0978279A1 (en) 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
AU5154699A (en) 1998-09-02 2000-03-27 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno(2,3-c)pyridine derivatives
DE69910045T2 (de) 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
WO2000021927A2 (en) 1998-10-08 2000-04-20 Smithkline Beecham Plc Pyrrole-2,5-diones as gsk-3 inhibitors
GB9905416D0 (en) 1999-03-09 1999-05-05 Allelix Biopharma Small molecules having GLP-2 like activity
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
US6080546A (en) 1999-07-23 2000-06-27 Isis Pharmaceuticals Inc. Antisense modulation of MEKK5 expression
US6030837A (en) 1999-08-03 2000-02-29 Isis Pharmaceuticals Inc. Antisense inhibition of PEPCK-mitochondrial expression
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
EP1572720A4 (en) 2002-05-24 2008-12-24 Nps Allelix Corp PROCESS FOR THE ENZYMATIC PRODUCTION OF GLP-2 (1-34) AND GLP-2 (1-33) PEPTIDES
EP2058309A4 (en) * 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
JP2010536917A (ja) * 2007-08-31 2010-12-02 メルク セローノ ソシエテ アノニム トリアゾロピリジン化合物と、ａｓｋ阻害剤としてのその化合物の利用法
EP2271646A1 (en) * 2008-03-31 2011-01-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
SI2531501T1 (sl) * 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze

Also Published As

Publication number Publication date
HRP20140114T1 (hr) 2014-03-14
US8802695B2 (en) 2014-08-12
CN102834393B (zh) 2015-07-22
CN102834393A (zh) 2012-12-19
RS53176B (sr) 2014-06-30
US9403819B2 (en) 2016-08-02
EP2531501B1 (en) 2013-11-20
WO2011097079A1 (en) 2011-08-11
SMT201400012B (it) 2014-03-07
PT2531501E (pt) 2014-02-17
ES2445917T3 (es) 2014-03-06
EP2531501A1 (en) 2012-12-12
DK2531501T3 (en) 2014-02-24
SI2531501T1 (sl) 2014-04-30
JP2013518881A (ja) 2013-05-23
US20120316194A1 (en) 2012-12-13
US20140329850A1 (en) 2014-11-06
CA2787360C (en) 2019-03-05
CA2787360A1 (en) 2011-08-11
JP5711270B2 (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
PL2531501T3 (pl) Inhibitory kinazy 1 regulującej sygnał apoptotyczny
IL247405A0 (en) Apoptosis signal-regulating kinase inhibitors
IL257965A (en) Apoptosis signal-regulated kinase inhibitor
PL2454250T3 (pl) Inhibitory kinazy regulującej sygnał apoptozy
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
PL2710007T3 (pl) Inhibitory kinazy
ZA201404156B (en) Kinase inhibitors
IL229028A0 (en) Kinase inhibitors
GB201009731D0 (en) Kinase inhibitors
IL228103A0 (en) Amino-quinolines as kinase inhibitors
ZA201404157B (en) Kinase inhibitors
IL232725A0 (en) The compositions containing kinase inhibitors
GB201009730D0 (en) Kinase inhibitor compounds
GB201021161D0 (en) Casein kinase 1delta (CK1Delta) inhibitors